Improved quality of life in patients with no-option critical limb ischemia undergoing gene therapy with DVC1-0101

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Matsumoto, Takuya ^a   Tanaka, Michiko ^b   Yoshiya, Keiji ^a   Yoshiga, Ryosuke ^a   Matsubara, Yutaka ^a   Horiuchi Yoshida, Kumi ^b   Yonemitsu, Yoshikazu ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2;

AGED; ANGIOGENESIS; FEMALE; GENE THERAPY; GENETICS; HUMAN; ISCHEMIA; LOWER LIMB; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PAIN; PATHOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSIOLOGY; PROCEDURES; QUALITY OF LIFE; QUESTIONNAIRE; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENETIC THERAPY; HUMANS; ISCHEMIA; LOWER EXTREMITY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PAIN; PERIPHERAL ARTERIAL DISEASE; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84978700997     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30035     Document Type: Article

References (25)

1. Mughal, N. A., Russell, D. A., Ponnambalam, S. & Homer-Vanniasinkam, S. Gene therapy in the treatment of peripheral arterial disease. Br J Surg 99, 6-15 (2012).
2. Madonna, R. & Rokosh, G. Insights into gene therapy for critical limb ischemia: the devil is in the details. Vascul Pharmacol 57, 10-14 (2012).
3. Tiong, A. & Freedman, S. B. Gene therapy for cardiovascular disease: the potential of VEGF. Curr Opin Mol Ther 6, 151-159 (2004).
4. Takeshita, S. et al. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93, 662-670 (1994).
5. Sedighiani, F. & Nikol, S. Gene therapy in vascular disease. Surgeon 9, 326-335 (2011).
6. Davies, M. G. Critical limb ischemia: cell and molecular therapies for limb salvage. Methodist Debakey Cardiovasc J 8, 20-27 (2012).
7. Germani, A., Di Campli, C., Pompilio, G., Biglioli, P. & Capogrossi, M. C. Regenerative therapy in peripheral artery disease. Cardiovasc Ther 27, 289-304 (2009).
8. Baumgartner, I. et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97, 1114-1123 (1998).
9. Presta, M. et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16, 159-178 (2005).
10. Yonemitsu, Y. et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 18, 970-973 (2000).
11. Masaki, I. et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of VEGF165 but not of FGF-2. Circ Res 90, 966-973 (2002).
12. Onimaru, M. et al. Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res 91, 923-930 (2002).
13. Yonemitsu, Y. et al. DVC1-0101 to treat peripheral arterial disease: a phase I/IIa open-label dose-escalation clinical trial. Mol Ther 21, 707-714 (2013).
14. Sprengers, R. W. et al. Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg 52, 843-849 (2010).
15. Lederman, R. J. et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 359, 2053-2058 (2002).
16. Killewich, L. A. Improving functional status and quality of life in elderly patients with peripheral arterial disease. J Am Coll Surg 202, 345-355 (2006).
17. Amer, M. S., Alsadany, M. A., Tolba, M. F. & Omer, O. H. Quality of life in elderly diabetic patients with peripheral arterial disease. Geriatr Gerontol Int 13, 443-450 (2013).
18. Rajagopalan, S. et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108, 1933-1938 (2003).
19. Hernandez-Osma, E., Cairols, M. A., Marti, X., Barjau, E. & Riera, S. Impact of treatment on the quality of life in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg 23, 491-494 (2002).
20. Culverwell, A. D., Tapping, C. R., Ettles, D. F. & Kessel, D. Patient experience, pain, and quality of life after lower limb angioplasty: a multisite prospective cohort study. Cardiovasc Intervent Radiol 35, 788-794 (2012).
21. Shigematsu, H. et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 17, 1152-1161 (2010).
22. Fukuhara, S., Bito, S., Green, J., Hisako, A. & Kurokawa, K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 51, 1037-1044 (1998).
23. Fukuhara, S., Ware, J. E., Kosinski, M., Wada, S. & Gandek, B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51, 1045-1053 (1998).
24. Suzukamo, Y. et al. Validation testing of a three-component model of Short Form-36 scores. J Clin Epidemiol 64, 3 (2011).
25. Aboyans, V. et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 126, 2890-2909 (2012).